XNCR
Xencor Inc
$12.33
+1.99%
$914.2M
No data for this timeframe.
Vol
Market Cap$914.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders50 funds
Inst. Value$592.2M
Inst. Activity10 buys / 3 sells
Insider Activity0B / 8S
Insider Net $-$441.1K
SEC Reports6
Recent Activity
May 6, 2026
SEC
Xencor reported Q1 2026 revenue of $4.5M (down 86% YoY) and a net loss of $128.9M ($1.71 per share), massively missing c
8-K — Impact 7/10
May 5, 2026
SEC
Xencor reported final Phase 1 data for XmAb942, an anti-TL1A antibody for IBD, showing a terminal half-life of 74.1 days
8-K — Impact 7/10
Apr 27, 2026
SEC
Xencor adopted an Executive Severance Policy covering VPs and above (excluding CEO), providing lump-sum base salary (15
8-K — Impact 3/10
Apr 10, 2026
Insider
Cornelissen Bart Jan sold 3,499 shares
SR. VICE PRESIDENT & CFO @ $12.29 ($43.0K)
Mar 6, 2026
Insider
Dahiyat Bassil I sold 6,606 shares
PRESIDENT & CEO @ $11.02 ($72.8K)
Mar 6, 2026
Insider
Desjarlais John R sold 2,502 shares
SR. VICE PRESIDENT & CSO @ $11.02 ($27.6K)
Inst.
RA CAPITAL MANAGEMENT, L.P. — NEW
4,897,237 shares ($59.1M)
Inst.
BANK OF AMERICA CORP — TRIM
366,093 shares ($4.4M)
Price Targets
$28.50
+131.1% upside
Strong Buy
Current $12.33
Low $14.00
Median $28.00
High $43.00
12 analysts
$14.00
$43.00
Analyst Ratings
6Strong Buy
11Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | JP Morgan | MAINTAIN | Neutral → Neutral |
| Mar 24, 2026 | JP Morgan | DOWNGRADE | Overweight → Neutral |
| Feb 26, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Dec 17, 2025 | Barclays | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.83 ▼ -9.3% | $-1.08 — $-0.65 | -103% YoY | 11 |
| Next Q | $-0.82 ▼ -6.9% | $-1.11 — $-0.50 | -926% YoY | 11 |
| Current FY | $-3.99 ▼ -29.8% | $-5.04 — $-2.98 | -222% YoY | 12 |
| Next FY | $-3.56 ▼ -17.0% | $-4.76 — $-2.20 | 11% YoY | 12 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $157.2M | — |
| RTW INVESTMENTS, LP | $81.7M | DOUBLED |
| RA CAPITAL MANAGEMENT, L.P. | $59.1M | NEW |
| STATE STREET CORP | $52.5M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $42.2M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 10, 2026 | Cornelissen Bart | SELL | $43.0K |
| Mar 6, 2026 | Dahiyat Bassil | SELL | $72.8K |
| Mar 6, 2026 | Desjarlais John | SELL | $27.6K |
| Mar 6, 2026 | Eckert Celia | SELL | $19.5K |
| Mar 5, 2026 | Dahiyat Bassil | SELL | $167.2K |
50 institutional holders with $592.2M total value (49,113,005 shares) as of 2026-Q1. Top holders: BlackRock,, RTW, RA. Net buying activity: 10 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 13,035,918 | $157.2M | 26.5% | — |
| 2 | RTW INVESTMENTS, LP | 6,777,461 | $81.7M | 13.8% | DOUBLED +158.9% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 4,897,237 | $59.1M | 10.0% | NEW |
| 4 | STATE STREET CORP | 4,352,036 | $52.5M | 8.9% | — |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3,500,342 | $42.2M | 7.1% | — |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3,101,647 | $37.4M | 6.3% | — |
| 7 | MORGAN STANLEY | 1,558,290 | $18.8M | 3.2% | ADD +67.5% |
| 8 | DIMENSIONAL FUND ADVISORS LP | 1,294,887 | $15.6M | 2.6% | — |
| 9 | BAKER BROS. ADVISORS LP | 1,102,106 | $13.3M | 2.2% | ADD +64.4% |
| 10 | Legal & General Group Plc | 1,066,780 | $12.9M | 2.2% | DOUBLED +603.7% |
| 11 | TWO SIGMA INVESTMENTS, LP | 805,421 | $9.7M | 1.6% | TRIM -57.3% |
| 12 | GOLDMAN SACHS GROUP INC | 763,793 | $9.2M | 1.6% | — |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 696,854 | $8.4M | 1.4% | — |
| 14 | PANAGORA ASSET MANAGEMENT INC | 620,756 | $7.5M | 1.3% | ADD +27.0% |
| 15 | TORONTO DOMINION BANK | 491,000 | $5.9M | 1.0% | DOUBLED +882.0% |
| 16 | Hudson Bay Capital Management LP | 487,320 | $5.9M | 1.0% | — |
| 17 | VANGUARD FIDUCIARY TRUST CO | 471,076 | $5.7M | 1.0% | — |
| 18 | Erste Asset Management GmbH | 430,200 | $4.9M | 0.8% | ADD +26.3% |
| 19 | CITADEL ADVISORS LLC | 377,699 | $4.6M | 0.8% | DOUBLED +118.4% |
| 20 | BANK OF AMERICA CORP /DE/ | 366,093 | $4.4M | 0.7% | TRIM -41.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 4,897,237 | — | $59.1M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 629,408 | 366,093 | -41.8% | $4.4M | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 47,189 | 82,534 | +74.9% | $995.4K | 2026-Q1 |
| HSBC HOLDINGS PLC | DOUBLED | 20,969 | 58,579 | +179.4% | $717.0K | 2026-Q1 |
| Trexquant Investment LP | TRIM | 175,152 | 44,491 | -74.6% | $536.6K | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | ADD | 34,794 | 43,818 | +25.9% | $528.4K | 2026-Q1 |
| Brevan Howard Capital Management LP | ADD | 23,051 | 42,684 | +85.2% | $514.8K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 34,158 | 18,723 | -45.2% | $225.8K | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 449 | 17,018 | +3690.2% | $205.2K | 2026-Q1 |
| CWM, LLC | ADD | 7,376 | 10,013 | +35.8% | $120.8K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | DOUBLED | 5,277 | 18,459 | +249.8% | $97.8K | 2026-Q1 |
| FEDERATED HERMES, INC. | ADD | 1,548 | 2,059 | +33.0% | $24.8K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 690 | 974 | +41.2% | $11.7K | 2026-Q1 |
| MORGAN STANLEY | ADD | 900,837 | 1,508,727 | +67.5% | $23.1M | 2025-Q4 |
| TORONTO DOMINION BANK | DOUBLED | 50,000 | 491,000 | +882.0% | $7.5M | 2025-Q4 |
| Erste Asset Management GmbH | ADD | 380,200 | 480,200 | +26.3% | $7.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 629,376 | 268,737 | -57.3% | $4.1M | 2025-Q4 |
| Trexquant Investment LP | ADD | 136,110 | 175,152 | +28.7% | $2.7M | 2025-Q4 |
| Rafferty Asset Management, LLC | ADD | 69,876 | 97,749 | +39.9% | $1.5M | 2025-Q4 |
| FMR LLC | ADD | 73,930 | 92,883 | +25.6% | $1.4M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 54,740 | 79,667 | +45.5% | $1.2M | 2025-Q4 |
| ALPS ADVISORS INC | ADD | 34,033 | 58,639 | +72.3% | $897.8K | 2025-Q4 |
| Russell Investments Group, Ltd. | DOUBLED | 12,004 | 47,189 | +293.1% | $722.5K | 2025-Q4 |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 18,551 | 38,825 | +109.3% | $594.4K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 190,389 | 34,158 | -82.1% | $523.0K | 2025-Q4 |
4 unique insiders with 8 transactions. Net insider value: -$441.1K ($0.00 bought, $441.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 10, 2026 | Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO | SELL | 3,499 | $12.29 | $43.0K |
| Mar 6, 2026 | Dahiyat Bassil I | PRESIDENT & CEO | SELL | 6,606 | $11.02 | $72.8K |
| Mar 6, 2026 | Desjarlais John R | SR. VICE PRESIDENT & CSO | SELL | 2,502 | $11.02 | $27.6K |
| Mar 6, 2026 | Eckert Celia | SVP, GENERAL COUNSEL | SELL | 1,767 | $11.02 | $19.5K |
| Mar 5, 2026 | Dahiyat Bassil I | PRESIDENT & CEO | SELL | 14,870 | $11.25 | $167.2K |
| Mar 5, 2026 | Desjarlais John R | SR. VICE PRESIDENT & CSO | SELL | 4,118 | $11.25 | $46.3K |
| Mar 5, 2026 | Eckert Celia | SVP, GENERAL COUNSEL | SELL | 3,244 | $11.25 | $36.5K |
| Mar 5, 2026 | Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO | SELL | 2,517 | $11.25 | $28.3K |
6 SEC filing reports analyzed. Sentiment: 2 bullish, 2 bearish, 0 mixed, 2 neutral. Avg impact: 5.8/10.
BEARISH
8-K
7/10
Xencor reported Q1 2026 revenue of $4.5M (down 86% YoY) and a net loss of $128.9M ($1.71 per share),
May 6, 2026
BULLISH
8-K
7/10
Xencor reported final Phase 1 data for XmAb942, an anti-TL1A antibody for IBD, showing a terminal ha
May 5, 2026
NEUTRAL
8-K
3/10
Xencor adopted an Executive Severance Policy covering VPs and above (excluding CEO), providing lump-
Apr 27, 2026
NEUTRAL
CLUSTER
3/10
Five open-market share sales by three Xencor executives—CEO, CFO, and General Counsel—over two days,
Mar 9, 2026
BEARISH
8-K
8/10
Xencor Inc. announced that Alexion Pharmaceuticals disputes its obligation to pay U.S. royalties on
Mar 4, 2026
BULLISH
8-K
7/10
Xencor reported financial results for Q4 and full year 2025, showing increased revenue and improved
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (85% buy). Based on 20 analysts: 6 strong buy, 11 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$28.50 mean target
+131.1% upside
Strong Buy (1.50)
$14.00 Low
$43.00 High
| Metric | Value |
|---|---|
| Current Price | $12.33 |
| Target Low | $14.00 |
| Target Mean | $28.50 |
| Target Median | $28.00 |
| Target High | $43.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.83 | $-1.08 | $-0.65 | -103.0% | -9.3% | 4↑ 6↓ | $0.0B | -56.5% | 11 |
| Next Q 2026-09-30 |
$-0.82 | $-1.11 | $-0.50 | -925.9% | -6.9% | 4↑ 6↓ | $0.0B | 2.0% | 11 |
| Current FY 2026-12-31 |
$-3.99 | $-5.04 | $-2.98 | -222.1% | -29.8% | 1↑ 11↓ | $0.1B | -41.9% | 12 |
| Next FY 2027-12-31 |
$-3.56 | $-4.76 | $-2.20 | 10.9% | -17.0% | 2↑ 9↓ | $0.1B | 51.3% | 12 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.832 | |
| 7d ago | $-0.761 | -0.071 |
| 30d ago | $-0.761 | -0.071 |
| 60d ago | $-0.761 | -0.071 |
| 90d ago | $-0.641 | -0.192 |
2 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Mar 24, 2026 | JP Morgan | DOWNGRADE | Overweight | Neutral |
| Feb 26, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Dec 17, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% | |
| May 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% | |
| Apr 1, 2026 | 6 | 11 | 3 | 0 | 0 | 85% | |
| Mar 1, 2026 | 6 | 12 | 2 | 0 | 0 | 90% | |
| Feb 1, 2026 | 6 | 12 | 2 | 0 | 0 | 90% | |
| Jan 1, 2026 | 6 | 12 | 2 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings_calendar
XNCR Q1 2026 Earnings Scheduled — 2026-05-13
May 5, 2026
earnings_calendar
XNCR Q1 2026 Earnings Scheduled — 2026-05-05
Mar 4, 2026
earnings_calendar
XNCR Q4 2025 Earnings After Market Close — 2026-03-04